Skip to main content

Table 2 Toxicity profile

From: A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma

 

All courses (total N = 36)

 

Grade 1

Grade 2

Grade 3

Total

Neutropeniaa

N/A

6 (16.7%)

5 (13.9%)

11 (30.1%)

Thrombocytopeniaa

N/A

10 (27.8%)

5 (13.9%)

15 (41.7%)

Bilirubina

N/A

2 (5.6%)

0 (0.0%)

2 (5.6%)

AST/ALTa

N/A

1 (2.8%)

1 (2.8%)

2 (5.6%)

Asthenia

4 (11.1%)

3 (8.3%)

1 (2.8%)

8 (22.2%)

Anorexia

10 (27.8%)

2 (5.6%)

0 (0.0%)

12 (33.3%)

Nausea

13 (36.1%)

0 (0.0%)

0 (0.0%)

13 (36.1%)

Vomit

5 (13.9%)

0 (0.0%)

0 (0.0%)

5 (13.9%)

Abdominal pain

7 (19.4%)

1 (2.8%)

0 (0.0%)

8 (22.2%)

Stomatitis

8 (22.2%)

1 (2.8%)

0 (0.0%)

9 (25%)

Diarrhea

8 (22.2%)

3 (8.3%)

3 (8.3%)

14 (38.9%)

Constipation

5 (13.9%)

2 (5.6%)

0 (0.0%)

7 (19.4%)

Sensory neuropathy

14 (38.9%)

4 (11.1%)

1 (2.8%)

19 (52.8%)

Motor neuropathy

0 (0.0%)

1 (2.8%)

0 (0.0%)

1 (2.8%)

Skin rash

2 (5.6%)

1 (2.8%)

0 (0.0%)

3 (8.3%)

  1. Abbreviations: AST Aspartate aminotransferase, ALT Alanine aminotransferase, N/A not assessed
  2. aToxicities with Grade 2 or more were counted for these items